Eliav Barr gave kudos to Eli Lilly for testing the company’s Zepbound weight loss drug in combination with a psoriatic arthritis drug to achieve better results for the underlying inflammation.
The post What Merck’s Chief Medical Officer Thinks of Lilly’s Approach to GLP-1s appeared first on MedCity News.
